Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Need for routine examination of left ventricular ejection fraction in patients with AML.

Khan HM, Gardner KM, Shaw C, Halpern AB, Huebner EM, Percival MM, Mirahsani S, Sorror ML, Becker PS, Walter RB, Estey EH.

Leukemia. 2019 Nov 12. doi: 10.1038/s41375-019-0637-z. [Epub ahead of print] No abstract available.

PMID:
31719680
2.

Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

Bone Marrow Transplant. 2019 Nov 4. doi: 10.1038/s41409-019-0739-2. [Epub ahead of print] No abstract available.

PMID:
31685932
3.

Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.

Othus M, Gale RP, Hourigan CS, Walter RB.

Bone Marrow Transplant. 2019 Oct 30. doi: 10.1038/s41409-019-0729-4. [Epub ahead of print]

PMID:
31666655
4.

Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia.

Bezerra ED, Othus M, Shawn C, Percival ME, Gardner K, Walter RB, Becker PS, Hendrie PC, Estey EH.

Clin Lymphoma Myeloma Leuk. 2019 Aug 1. pii: S2152-2650(19)30632-9. doi: 10.1016/j.clml.2019.06.014. [Epub ahead of print] No abstract available.

PMID:
31648955
5.

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.

Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, Hartley GA, Welch VL, Estey EH, Walter RB.

Leukemia. 2019 Oct 4. doi: 10.1038/s41375-019-0586-6. [Epub ahead of print] No abstract available.

PMID:
31586148
6.

Novel monoclonal antibody-based therapies for acute myeloid leukemia.

Morsink LM, Walter RB.

Best Pract Res Clin Haematol. 2019 Jun;32(2):116-126. doi: 10.1016/j.beha.2019.05.002. Epub 2019 May 9. Review.

PMID:
31203993
7.

Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas.

Klotz B, Kneitz S, Lu Y, Boswell W, Postlethwait J, Warren W, Walter RB, Schartl M.

G3 (Bethesda). 2019 Jul 9;9(7):2267-2276. doi: 10.1534/g3.119.400051.

8.

Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?

Vaughn JE, Shankaran V, Walter RB.

Curr Hematol Malig Rep. 2019 Jun;14(3):171-178. doi: 10.1007/s11899-019-00510-2. Review.

PMID:
31079354
9.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.208678. doi: 10.3324/haematol.2018.208678. [Epub ahead of print]

10.

Fluorescent Light Incites a Conserved Immune and Inflammatory Genetic Response within Vertebrate Organs (Danio Rerio, Oryzias Latipes and Mus Musculus).

Boswell M, Lu Y, Boswell W, Savage M, Hildreth K, Salinas R, Walter CA, Walter RB.

Genes (Basel). 2019 Apr 3;10(4). pii: E271. doi: 10.3390/genes10040271.

11.

A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia.

Mamolo CM, Cappelleri JC, Hoang CJ, Kim R, Hadfield A, Middleton C, Rider A, Walter RB.

Future Oncol. 2019 Jun;15(16):1895-1909. doi: 10.2217/fon-2018-0842. Epub 2019 Mar 26.

PMID:
30912462
12.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ.

J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.

PMID:
30892988
13.

Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.

Buckley SA, Mark NM, Othus M, Estey EH, Patel K, Walter RB.

Leuk Lymphoma. 2019 Sep;60(9):2304-2307. doi: 10.1080/10428194.2019.1581933. Epub 2019 Mar 11. No abstract available.

PMID:
30856024
14.

Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.

Godwin CD, Fromm JR, Othus M, Sandmaier BM, Mielcarek MB, Wood BL, Appelbaum FR, Storb R, Walter RB.

Bone Marrow Transplant. 2019 Sep;54(9):1511-1514. doi: 10.1038/s41409-019-0481-9. Epub 2019 Feb 25. No abstract available.

PMID:
30804488
15.

Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.

Lu Y, Boswell W, Boswell M, Klotz B, Kneitz S, Regneri J, Savage M, Mendoza C, Postlethwait J, Warren WC, Schartl M, Walter RB.

Sci Rep. 2019 Jan 24;9(1):530. doi: 10.1038/s41598-018-36656-x.

16.

In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia.

McGuffin SA, Bharadwaj R, Gonzalez-Cuyar LF, Schiffer JT, Stacey AW, Walter RB, Duke ER.

Clin Infect Dis. 2019 Jan 18;68(3):525-529. doi: 10.1093/cid/ciy394. No abstract available.

PMID:
30657904
17.

Outpatient induction and consolidation care strategies in acute myeloid leukemia.

Halpern AB, Walter RB, Estey EH.

Curr Opin Hematol. 2019 Mar;26(2):65-70. doi: 10.1097/MOH.0000000000000481.

PMID:
30585894
18.

CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia.

Halpern AB, Walter RB.

Oncotarget. 2018 Nov 27;9(93):36543-36544. doi: 10.18632/oncotarget.26383. eCollection 2018 Nov 27. No abstract available.

19.

Refining AML outcome prediction.

Hourigan CS, Gale RP, Walter RB.

Leukemia. 2019 Feb;33(2):283-284. doi: 10.1038/s41375-018-0317-4. Epub 2018 Dec 14. No abstract available.

PMID:
30552400
20.

Long-term experimental hybridisation results in the evolution of a new sex chromosome in swordtail fish.

Franchini P, Jones JC, Xiong P, Kneitz S, Gompert Z, Warren WC, Walter RB, Meyer A, Schartl M.

Nat Commun. 2018 Dec 3;9(1):5136. doi: 10.1038/s41467-018-07648-2.

21.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. No abstract available.

22.

Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.

Morsink LM, Walter RB, Ossenkoppele GJ.

Blood Rev. 2019 Mar;34:26-33. doi: 10.1016/j.blre.2018.10.003. Epub 2018 Nov 1. Review.

PMID:
30401586
23.

Workshop report: Cryopreservation of aquatic biomedical models.

Hagedorn M, Varga Z, Walter RB, Tiersch TR.

Cryobiology. 2019 Feb;86:120-129. doi: 10.1016/j.cryobiol.2018.10.264. Epub 2018 Oct 31.

PMID:
30389588
24.

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.

Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2019 Feb;33(2):554-558. doi: 10.1038/s41375-018-0274-y. Epub 2018 Oct 12. No abstract available.

25.

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.

Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo RR, Kiem HP, Walter RB.

Leukemia. 2019 Mar;33(3):762-808. doi: 10.1038/s41375-018-0277-8. Epub 2018 Oct 5. No abstract available.

PMID:
30291334
26.

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH.

Leuk Lymphoma. 2019 Apr;60(4):1023-1029. doi: 10.1080/10428194.2018.1516036. Epub 2018 Oct 2.

PMID:
30277112
27.

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.

Klupsch K, Baeriswyl V, Scholz R, Dannenberg J, Santimaria R, Senn D, Kage E, Zumsteg A, Attinger-Toller I, von der Bey U, König-Friedrich S, Dupuy F, Lembke W, Albani C, Wendelspiess S, Dinkel L, Saro D, Hepler RW, Laszlo GS, Gudgeon CJ, Bertschinger J, Brack S, Walter RB.

Leukemia. 2019 Mar;33(3):805-808. doi: 10.1038/s41375-018-0249-z. Epub 2018 Sep 11. No abstract available.

PMID:
30206306
28.

Analysis of the putative tumor suppressor gene cdkn2ab in pigment cells and melanoma of Xiphophorus and medaka.

Regneri J, Klotz B, Wilde B, Kottler VA, Hausmann M, Kneitz S, Regensburger M, Maurus K, Götz R, Lu Y, Walter RB, Herpin A, Schartl M.

Pigment Cell Melanoma Res. 2019 Mar;32(2):248-258. doi: 10.1111/pcmr.12729. Epub 2018 Sep 6.

PMID:
30117276
29.

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.

Laszlo GS, Beddoe ME, Godwin CD, Bates OM, Gudgeon CJ, Harrington KH, Walter RB.

Haematologica. 2019 Feb;104(2):e59-e62. doi: 10.3324/haematol.2018.202069. Epub 2018 Aug 16. No abstract available.

30.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.

31.

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML).

Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EH.

J Drug Assess. 2018 Jul 10;7(1):51-53. doi: 10.1080/21556660.2018.1492925. eCollection 2018.

32.

Evaluating measurable residual disease in acute myeloid leukemia.

Ravandi F, Walter RB, Freeman SD.

Blood Adv. 2018 Jun 12;2(11):1356-1366. doi: 10.1182/bloodadvances.2018016378. Review.

33.

Next-generation sequencing for measuring minimal residual disease in AML.

Walter RB, Appelbaum FR.

Nat Rev Clin Oncol. 2018 Aug;15(8):473-474. doi: 10.1038/s41571-018-0040-0. No abstract available.

PMID:
29795270
34.

Waveband specific transcriptional control of select genetic pathways in vertebrate skin (Xiphophorus maculatus).

Walter RB, Boswell M, Chang J, Boswell WT, Lu Y, Navarro K, Walter SM, Walter DJ, Salinas R, Savage M.

BMC Genomics. 2018 May 10;19(1):355. doi: 10.1186/s12864-018-4735-5.

35.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.

36.

Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

Michaelis LC, Klepin HD, Walter RB.

Expert Opin Pharmacother. 2018 Jun;19(8):865-882. doi: 10.1080/14656566.2018.1465562. Epub 2018 Apr 26. Review.

PMID:
29697000
37.

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1615-1620. doi: 10.1016/j.bbmt.2018.04.017. Epub 2018 Apr 21.

38.

Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?

Walter RB.

J Clin Oncol. 2018 May 20;36(15):1463-1465. doi: 10.1200/JCO.2018.78.3266. Epub 2018 Apr 6. No abstract available.

PMID:
29624462
39.

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.

Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB.

Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31. No abstract available.

40.

Investigational CD33-targeted therapeutics for acute myeloid leukemia.

Walter RB.

Expert Opin Investig Drugs. 2018 Apr;27(4):339-348. doi: 10.1080/13543784.2018.1452911. Epub 2018 Mar 15. Review.

PMID:
29534618
41.

Clonal polymorphism and high heterozygosity in the celibate genome of the Amazon molly.

Warren WC, García-Pérez R, Xu S, Lampert KP, Chalopin D, Stöck M, Loewe L, Lu Y, Kuderna L, Minx P, Montague MJ, Tomlinson C, Hillier LW, Murphy DN, Wang J, Wang Z, Garcia CM, Thomas GCW, Volff JN, Farias F, Aken B, Walter RB, Pruitt KD, Marques-Bonet T, Hahn MW, Kneitz S, Lynch M, Schartl M.

Nat Ecol Evol. 2018 Apr;2(4):669-679. doi: 10.1038/s41559-018-0473-y. Epub 2018 Feb 12.

42.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

43.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

44.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.

45.

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.

Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4. No abstract available.

46.

Expression signatures of early-stage and advanced medaka melanomas.

Klotz B, Kneitz S, Regensburger M, Hahn L, Dannemann M, Kelso J, Nickel B, Lu Y, Boswell W, Postlethwait J, Warren W, Kunz M, Walter RB, Schartl M.

Comp Biochem Physiol C Toxicol Pharmacol. 2018 Jun;208:20-28. doi: 10.1016/j.cbpc.2017.11.005. Epub 2017 Nov 21.

47.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.

Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.

48.

The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.

Buccisano F, Hourigan CS, Walter RB.

Curr Hematol Malig Rep. 2017 Dec;12(6):547-556. doi: 10.1007/s11899-017-0420-z. Review.

PMID:
29027628
49.

The Novel Evolution of the Sperm Whale Genome.

Warren WC, Kuderna L, Alexander A, Catchen J, Pérez-Silva JG, López-Otín C, Quesada V, Minx P, Tomlinson C, Montague MJ, Farias FHG, Walter RB, Marques-Bonet T, Glenn T, Kieran TJ, Wise SS, Wise JP Jr, Waterhouse RM, Wise JP Sr.

Genome Biol Evol. 2017 Dec 1;9(12):3260-3264. doi: 10.1093/gbe/evx187. Erratum in: Genome Biol Evol. 2018 Apr 1;10(4):1063.

50.

Fluorescent light exposure incites acute and prolonged immune responses in zebrafish (Danio rerio) skin.

Gonzalez TJ, Lu Y, Boswell M, Boswell W, Medrano G, Walter S, Ellis S, Savage M, Varga ZM, Lawrence C, Sanders G, Walter RB.

Comp Biochem Physiol C Toxicol Pharmacol. 2018 Jun;208:87-95. doi: 10.1016/j.cbpc.2017.09.009. Epub 2017 Sep 29.

Supplemental Content

Loading ...
Support Center